Verici Dx (LON:VRCI) Hits New 1-Year Low – Here’s What Happened

Verici Dx plc (LON:VRCI) hit a new 52-week low on Monday . The company traded as low as GBX 4 ($0.05) and last traded at GBX 4 ($0.05), with a volume of 210052 shares traded. The stock had previously closed at GBX 4.25 ($0.06).

Verici Dx Trading Down 3.4 %

The stock has a market cap of £8.49 million, a price-to-earnings ratio of -162.50 and a beta of 1.59. The business has a 50-day simple moving average of GBX 6.31 and a two-hundred day simple moving average of GBX 6.98. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.54 and a quick ratio of 8.49.

About Verici Dx

Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.